R
Rivermark Medical
Minimally invasive treatment for Benign Prostatic Hyperplasia, restoring urinary function and enabling early return to daily life
About Rivermark Medical
Rivermark Medical specializes in developing minimally invasive treatments for Benign Prostatic Hyperplasia (BPH), a condition that affects the prostate gland in men, leading to urinary problems. The company's flagship product rapidly restores urinary function, allowing patients to return to their normal daily activities sooner. Rivermark Medical operates in the medical device industry, targeting urologists and healthcare providers who treat BPH. The business model focuses on the commercialization of its proprietary medical devices, generating revenue through sales to hospitals, clinics, and medical practitioners. The company leverages the expertise of its leadership team, which includes experienced executives and medical professionals with backgrounds in biomedical engineering and urology. Rivermark Medical aims to be the preferred first-line device therapy for BPH, offering a solution that is both effective and minimally invasive.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Milwaukee, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 54.8/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, medical implants, Surgery, Chronic Disease, Hard Tech, urinary, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Rivermark Medical.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | May 2026 | $20M | $150M | Andera Partners | ↗ |
| SERIES COther financing | Oct 2024 | $30M | $120M | Venture Investors Health Fund · Time BioVentures · View Ventures · American Century Investments | ↗ |
Growth signals
Latest recorded traffic for Rivermark Medical is 740 monthly website visits, down 9.8% over the last three months. Rivermark Medical's team grew 21.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
American Century Investments
Venture Investors Health Fund
Time BioVentures- VVView Ventures
Cadence Healthcare Ventures
Andera Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rivermark Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rivermark Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






